Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M versus AMINOSYN II 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 M versus AMINOSYN II 3 5 IN PLASTIC CONTAINER.
AMINOSYN 3.5% M vs AMINOSYN II 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a crystalline amino acid solution providing essential and nonessential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It acts as a substrate for anabolic processes and helps correct negative nitrogen balance.
Aminosyn II 3.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis and maintenance of nitrogen balance. The amino acids serve as substrates for protein synthesis, and their metabolism yields nitrogen for ureagenesis and carbon skeletons for gluconeogenesis or oxidation.
Intravenous infusion; typical adult dose: 1 to 1.5 g amino acids/kg/day (equivalent to 28.6 to 42.9 mL/kg/day of 3.5% solution). Administer via central or peripheral line at a rate not exceeding 0.5 g amino acids/kg/hour.
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour (equivalent to 0.035-0.07 g amino acids/kg/hour) for protein supplementation, not to exceed 0.2 g nitrogen/kg/day. Dosage individualized based on metabolic needs and clinical response.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is typically 0.5-2 hours in patients with normal renal and metabolic function, reflecting rapid uptake and metabolism by tissues. In hepatic or renal impairment, half-life may be prolonged due to decreased clearance.
The terminal elimination half-life of infused amino acids is not typically defined as a single value because they are rapidly cleared from plasma for protein synthesis and metabolic processes. For labeled amino acids, the plasma clearance half-life ranges from 10-30 minutes. Clinically, the half-life is short; continuous infusion is required to maintain plasma amino acid levels. In patients with hepatic or renal dysfunction, half-life may be prolonged.
Amino acids in Aminosyn 3.5% M are primarily eliminated via metabolism (utilization for protein synthesis, energy, and other metabolic pathways). Minimal amounts are excreted unchanged in urine (less than 5% of infused amino acids) via glomerular filtration. There is no significant biliary or fecal elimination.
Aminosyn II 3.5% is a crystalline amino acid solution. The amino acids are metabolized and utilized for protein synthesis. Excess nitrogen is converted to urea in the liver and excreted renally as urea. Approximately 80-90% of infused amino acids are incorporated into proteins or metabolized; the remainder is excreted in urine as urea and other nitrogenous wastes. Fecal excretion is negligible (less than 2%) as amino acids are not significantly eliminated in bile. In patients with renal impairment, urea excretion is decreased, leading to azotemia.
Category C
Category C
Amino Acid Solution
Amino Acid Solution